Depression (June/July)

Date of Issue: 06/01/2021 | Volume: 19 | Number: 6&7

Issue Links:Learning Objectives | Editorial Information

Giovanni Fava details therapeutic options for preventing depression. John Nurnberger clarifies which pharmacogenetic tests are ready for prime time.

In This Issue

Editor’s Note

Note From the Editor-in-Chief

Black-and-white ideas don’t fit well in psychiatry, but they sometimes seep into my work nonetheless. There they nestle into some corner of uncertainty, making things a little more comfortable than they ought to be. In this issue, I expunge a few of them, with a little help from our friends.

Read More
Clinical Update

Disulfiram: An Underused Strategy for Alcohol Use Disorders

Topics: Abstinence | Addiction | Addiction Treatment | Alcohol | Alcohol Use | Alcohol use disorder | Alcoholism | Disulfiram | Psychopharm Myths

We unravel the myths that keep psychiatrists from using disulfiram (Antabuse) in alcohol use disorders. In the right patient, this medication is very effective and far less dangerous than the alternative: continued drinking.

Read More
Expert Q&A

Psychotherapy and Medication in Recurrent Depression

Topics: Brief psychotherapy | Deprescribing | Depression | Depressive Disorder | Prevention | Psychotherapy | Therapy during medication appointment | Therapy with Med Management | Treatment-Resistant Depression

Antidepressants treat depression, but patients need something more to prevent future episodes. Giovanni Fava describes an evidence-based method that blends medication with psychotherapy in two phases: sequential treatment for prevention of depression.

Read More
Clinical Update

How to Write an Open Note

Topics: Computers in Psychiatric Practice | Confidentiality | EHR | Electronic Health Records | electronic use | Engagement | HIPAA | Patient relationship | Privacy | retention

Medical notes may never be the same again. The Open Notes policy allows patients to read their record without delay, and nearly prevents doctors from withholding notes in the interest of safety. Here we share tips on how to use this policy to enhance the therapeutic relationship.

Read More
Expert Q&A

Genetic Testing: What You Need to Know in 2021

Topics: Autism Spectrum Disorder | CYP2C19 | CYP2D6 | GeneSight | Genetic Testing | Genetics and Psychiatry | Laboratory Testing in Psychiatry | Learning & Developmental Disabilities | Pharmacogenomics | Treatment-Resistant Depression | Whole Genome Sequencing

Is genetic testing ready for clinical practice? It depends on which test we’re talking about. In this interview John Nurnberger details the tests to pay attention to on a genetic panel and describes how to use whole exome sequencing (WES) to identify genetic causes of autism and intellectual disability.

Read More
Research Update

Two Negative Studies of Mirtazapine and Riluzole for PTSD in Veterans

Topics: Mirtazapine | PTSD | Randomized controlled trial | Research | Research Update | Riluzole | Trauma

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.

Read More
Research Update

Shining a Light on PTSD

Topics: Complementary treatments | Light therapy | Lightbox | natural treatments | PTSD | Randomized controlled trial | Research | Research Update | Seasonal Affective Disorder | Trauma

This first-of-its-kind study looked at lightbox in PTSD with a randomized, placebo-controlled design.

Read More
CME Post-Test

CME Post-Test - Depression, TCPR, June/July 2021

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.

Read More